Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Oral Progestin for Fertility-sparing in Early Endometrial Cancer
NCT03567655Phase 2Unknown
- Sponsor
- Asan Medical Center
- Start
- Jul 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of medroxyprogesterone acetate in endometrial adenocarcinoma, sponsored by Asan Medical Center. Status: unknown.
02
Drugs
medroxyprogesterone acetate
03
Conditions
endometrial adenocarcinoma
Beyond the preview
Go deeper on NCT03567655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03567655.